Radiation therapy after lumpectomy for breast cancer can be safely reduced to 4 weeks

Nov 04, 2009

Researchers at Fox Chase Cancer Center found that radiation treatment for women who had a lumpectomy for early-stage breast cancer can be safely reduced to four weeks, instead of the usual six to seven weeks, by delivering a higher daily dose--greatly reducing the length of treatment time. The five-year results of the phase II study will be presented today at the annual meeting of the American Society for Radiation Oncology.

The study showed that treatment time can be shortened from the historical six to seven weeks to just four weeks using IMRT (intensity-modulated radiation therapy), a highly sophisticated system of delivering external-beam radiation. This system uses advanced computer optimized planning and radiation delivery techniques that create more optimal dose distributions, greater sparing of the skin and lower doses to organs such as lung and heart--thus reducing potential side effects.

"When delivering high doses of radiation, we have to consider the level of side effects and the cosmetic result," explained Gary Freedman, M.D., radiation oncologist at Fox Chase. "In this phase II study, women reported acceptable side effects that were no different than would be expected from a usual, more prolonged length of treatment. In addition, with long term follow-up we see cure rates and cosmetic results that are similar to a longer six-week treatment course."

Using IMRT, this study examined the delivery of a higher daily dose of radiation over four weeks (versus a lower dose over six to seven weeks). Another way of reducing treatment length was by incorporating a "boost" into the same four weeks. The lumpectomy site where the tumor was removed is usually treated with a high-dose radiation "boost." The standard "boost" is typically administered after the five weeks of whole breast irradiation and can add another one to two weeks to the treatment time.

Freedman and his colleagues demonstrated that in addition to safely increasing the dose to the whole breast during the four-week period, it is possible to deliver the "boost" concurrently, eliminating the extra two weeks.

"This more accelerated treatment regimen should be an option for women who want to be treated in a shorter period of time," says Freedman. "This may particularly appeal to women who drive a long distance for radiation, have busy schedules at home or work, or have a large insurance co-pay for each daily ."

Freedman cautioned that this treatment schedule may not be for all women. "There may be patients who are uncomfortable with the idea of an accelerated treatment and want to be treated with a more conventional six to seven week course of treatment," he says. "In addition, we need more research to determine which women are ideal candidates for this treatment because of differences in anatomy or other treatments for their ."

The study included 75 women treated with 2.25 Gy for 20 days (versus 2 Gy per day with conventional therapy) and a 2.8 Gy boost concurrently (versus sequentially delivering the boost after whole breast irradiation). The risk of recurrence within five years in the treated breast was low-0.4%--which compares favorably to results with conventional radiation. In addition, patients and their physicians considered the cosmetic results good or excellent in most women.

Source: Fox Chase Cancer Center (news : web)

Explore further: Two studies identify a detectable, pre-cancerous state in the blood

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Gene test aids cancer profile

6 hours ago

The first round of chemotherapy did little to suppress Ron Bose's leukemia. The second round, with 10 times the dose, knocked the proliferating blast cells down, but only by half.

Hospital volume not linked to costs of cancer surgery

21 hours ago

(HealthDay)—Hospital surgical volume does not appear to correlate with Medicare payments for cancer surgery, according to research published online Nov. 24 in the Journal of Clinical Oncology.

How a common antacid could lead to cheaper anti-cancer drugs

23 hours ago

A popular indigestion medication can increase survival in colorectal cancer, according to research published in ecancermedicalscience. But in fact, scientists have studied this for years - and a group of cancer advocates want t ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.